Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

Key Inclusion Criteria: * Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive * Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) * Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening. If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or emtricitabine must have been stopped at least 12 weeks prior to screening * Documented hepatitis B virus DNA (HBV DNA) \< 400 copies/mL for at least 3.5 years prior to screening and at screening * ALT within normal range * α-fetoprotein (AFP) \<= 50 ng/mL * Calculated creatinine clearance \>= 70 mL/min by Cockcroft-Gault formula using ideal body weight * \<= 10 kPa on Fibroscan assessment * A negative serum pregnancy test for female subjects * Adult subjects \>= 18 years of age Key Exclusion Criteria: * Known cirrhosis * Evidence of fibrosis \>= Stage 3 (METAVIR) on liver biopsy or Fibroscan \> 10 kPa within 6 months prior to screening * Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA \> 400 copies/mL within 3.5 years prior to screening * History of decompensated liver disease (defined as direct \[conjugated\] bilirubin \> 1.5 x upper limit of normal, prothrombin time (PT) \> 1.5 x upper limit of normal, platelets \< 75,000/mm³, serum albumin \< 3.0 g/dL * History of clinical hepatic decompensation in the judgement of the investigator * Evidence of hepatocellular carcinoma * Significant bone disease (in the judgment of the investigator) * Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection * Known hypersensitivity to TDF, its metabolites, or formulation excipients * Concomitant therapy with disallowed medications * History of malignant disease * Lactating females * Females wishing to became pregnant during the duration of the stud * Subjects participating in another clinical trial can only be enrolled at the discretion of the Medical Monitor Note: Other protocol defined inclusion/Exclusion criteria may apply.